Washington University SPORE in Pancreatic Cancer

华盛顿大学 SPORE 在胰腺癌中的应用

• 批准号: 9982223
• 负责人: WILLIAM G HAWKINS
• 金额: $ 218.47万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-28 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9982223
• 关键词: Antineoplastic Agents; Basic Science; Biometry; Cancer Biology; Cancer Center; Cancer Research Project; Cancer Vaccines; Clinic; Clinical; Clinical Sciences; Clinical Trials; Collaborations; Dendritic Cells; Development; Diagnosis; Disabled Persons; Disease; Drug Monitoring; Drug Targeting; Drug Utilization; Ensure; Environment; Ethics; Female; Fostering; Genomics; Goals; Image; Immunologics; Immunology; Immunosuppression; Immunotherapy; Individual; Infrastructure; Institution; KRAS2 gene; Ligands; Malignant neoplasm of pancreas; Mentors; Minority; Mission; Morbidity - disease rate; Myeloid-derived suppressor cells; Nebraska; North Carolina; Pancreatic Ductal Adenocarcinoma; Pathway interactions; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Radiology Specialty; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Science; Specialized Program of Research Excellence; Testing; Therapeutic; Therapeutic Clinical Trial; Therapeutic Trials; Tissues; Training; Translational Research; Translations; Universities; Washington; Work; animal imaging; anti-tumor immune response; cancer therapy; career; clinical development; clinical practice; design; drug development; improved; inhibitor/antagonist; innovation; inter-institutional; leukemia; malignant breast neoplasm; migration; mortality; mutant; novel; novel diagnostics; novel imaging technique; novel strategies; novel therapeutic intervention; novel therapeutics; patient population; preclinical study; prevent; programs; recruit; response; small molecule inhibitor; small molecule therapeutics; translational cancer research; tumor; tumor microenvironment

PROJECT SUMMARY The Washington University Pancreatic Cancer Specialized Program of Research Excellence (SPORE) is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical sciences, and our teams leverage individual expertise in immunology, drug development, genomics, and imaging to develop novel diagnostic and therapeutic approaches to PDAC. This SPORE includes four research projects, an administrative core, two shared-resources cores, and developmental research and career enhancement programs. With the help of our External and Internal Advisory Boards, we have intentionally selected the projects that have the greatest potential to impact PDAC. All four of our selected projects include a therapeutic trial, and two take advantage of immunologic discoveries made at WU. We have two projects that utilize small molecule inhibitors of pathways that are known to be active in PDAC. The four projects in our application are designed to have significant potential to change clinical practice within five years. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy Project 2: Clinical Development of the Pancreatic Cancer Drug Conjugate SW V-49 Project 3: Combination Inhibition of ERK for Pancreatic Cancer Treatment Project 4: Translation and Preclinical Studies of a Personalized Pancreatic Cancer Vaccine Our long-term goal is to improve survival of patients diagnosed with PDAC. To achieve this, we will promote institutional and inter-institutional collaborative science, with an emphasis on translation. We expect that no singular approach will solve PDAC, and fully commit to supporting the development of novel ideas and young investigators. Our SPORE will provide access to pancreatic cancer-specific resources to facilitate this mission.

项目概要 华盛顿大学胰腺癌卓越研究专业计划 (SPORE) 是一个 高度转化的癌症研究计划完全专注于最致命的疾病——胰腺癌 导管腺癌（PDAC）。我们杰出的研究人员在基础和研究领域拥有互补的专业知识 临床科学，我们的团队利用免疫学、药物开发、基因组学方面的个人专业知识， 和成像技术来开发新的 PDAC 诊断和治疗方法。 该 SPORE 包括四个研究项目、一个管理核心、两个共享资源核心和 发展研究和职业提升计划。在我们外部和内部的帮助下 作为顾问委员会，我们特意选择了最有可能影响 PDAC 的项目。 我们选择的所有四个项目都包括治疗试验，其中两个项目利用了免疫学发现 在 WU 制作。我们有两个项目利用已知途径的小分子抑制剂 活跃于 PDAC。我们申请中的四个项目旨在具有改变临床的巨大潜力 五年内实践。 项目1：克服肿瘤引起的免疫抑制，改善免疫治疗的反应 项目2：胰腺癌药物偶联物SW V-49的临床开发 项目3：联合抑制ERK治疗胰腺癌 项目4：个性化胰腺癌疫苗的转化和临床前研究 我们的长期目标是提高 PDAC 患者的生存率。为了实现这一目标，我们将推动 机构和机构间合作科学，重点是翻译。我们预计不会 单一方法将解决PDAC，并全力支持新奇想法和年轻人的发展 调查人员。我们的 SPORE 将提供胰腺癌特定资源，以促进这一使命。

项目成果

Less is more in the difficult gallbladder: recent evolution of subtotal cholecystectomy in a single HPB unit.

在困难的胆囊中，少即是多：单个 HPB 单元中胆囊次全切除术的最新进展。

• 发表时间: 2021
• 作者: LeCompte, Michael T;Robbins, Keenan J;Williams, Greg A;Sanford, Dominic E;Hammill, Chet W;Fields, Ryan C;Hawkins, William G;Strasberg, Steven M
• 通讯作者: Strasberg, Steven M

Flange Gastroenterostomy Results in Reduction in Delayed Gastric Emptying after Standard Pancreaticoduodenectomy: A Prospective Cohort Study.

法兰胃肠造口术可减少标准胰十二指肠切除术后胃排空延迟：一项前瞻性队列研究。

• 发表时间: 2017-10
• 影响因子: 5.2
• 作者: Khan, Adeel S;Williams, Greg;Woolsey, Cheryl;Liu, Jingxia;Fields, Ryan C;Doyle, Majella M B;Hawkins, William G;Strasberg, Steven M
• 通讯作者: Strasberg, Steven M

Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).

使用循环肿瘤 DNA (ctDNA) 检测实体瘤分子残留疾病 (MRD)。

• 发表时间: 2019-06
• 影响因子: 4
• 作者: Chin, Re;Chen, Kevin;Usmani, Abul;Chua, Chanelle;Harris, Peter K;Binkley, Michael S;Azad, Tej D;Dudley, Jonathan C;Chaudhuri, Aadel A
• 通讯作者: Chaudhuri, Aadel A

Optimal design of longitudinal data analysis using generalized estimating equation models.

使用广义估计方程模型的纵向数据分析的优化设计。

• 发表时间: 2017-03
• 作者: Liu, Jingxia;Colditz, Graham A
• 通讯作者: Colditz, Graham A

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.

通过基于肽的纳米颗粒将 RAS 抑制 siRNA 精确递送至 KRAS 驱动的癌症。

• 发表时间: 2019-07-30
• 作者: Strand, Matthew S;Krasnick, Bradley A;Pan, Hua;Zhang, Xiuli;Bi, Ye;Brooks, Candace;Wetzel, Christopher;Sankpal, Narendra;Fleming, Timothy;Goedegebuure, S Peter;DeNardo, David G;Gillanders, William E;Hawkins, William G;Wickline, Samuel A;Fiel
• 通讯作者: Fiel